Skip to main content
. Author manuscript; available in PMC: 2014 Oct 6.
Published in final edited form as: Nanomedicine. 2013 Feb 18;9(6):758–766. doi: 10.1016/j.nano.2013.01.008

Table 1.

Characteristics of the studied samples, taken from different cell lines. Each cell line was grown in several replicas.

Oncogene Cell line Histology Patient type (source database) Tissue type Mutation
EGFRmut H3255 Adeno Non-smoker; female; Caucasian (Sanger) Lung L858R
H820 Adeno Male; Caucasian (ATCC) Lymph node EX19
H1650 Adeno Current-smoker; male; Caucasian (ATCC) Pleural effusion EX19
H1975 Adeno Non-smoker; Female (ATCC) Lung L858R; T790M
HCC4006 Adeno Male; Caucasian (ATCC) Pleural effusion EX19
HCC2279 Adeno Unknown (Sanger) Lung EX19
KRASmut A549 Adeno Male; Caucasian (ATCC) Lung G12S
H2009 Adeno Current-smoker; Female; Caucasian (ATCC) Lymph node G12A
H460 Large cell Male (ATCC) Pleural effusion Q61H
NE18 Squamous Unknown (Sanger) Lung n/aa
EML4-ALK H2228 Adeno Non-smoker; female (ATCC) Lung
Other oncogenes H322 Adeno Unknown (Sanger) Lung
  (wt to the above) H1703 Adeno Current-smoker; male; Caucasian (ATCC) Lung
H125 Adeno Unknown (Sanger) Lung
H1435 Adeno Non-smoker; female (ATCC) Lung
Calu3 Adeno Male; Caucasian (ATCC) Pleural effusion
HCC15 Squamous Male (Sanger) Lung
H520 Squamous Male (ATCC) Lung
HCC193 Adeno Unknown (Sanger) Lung
a

KRAS mutation was identified in NE-18 at the University of Colorado Cancer Center through direct sequencing, but the location of the mutation was not recorded.